American Journal of Cardiology
Volume 101, Issue 9 , Pages 1242-1246 , 1 May 2008

Factors Associated With Discharge Lipid-Lowering Drug Prescription in Patients Hospitalized for Coronary Artery Disease (from the Get With the Guidelines Database)

  • Nancy M. Albert, PhD

      Affiliations

    • Institute of Nursing and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationCorresponding author: Tel: 216-444-7028; fax: 216-445-1776.
    • ,
  • Kimberly K. Birtcher, MS, PharmD

      Affiliations

    • University of Houston College of Pharmacy, Houston, Texas
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • David C. Goff Jr., MD, PhD

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem North Carolina
    • ,
  • Jyotsna Mulgund, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • Li Liang, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • Department of Medicine, UCLA Medical Center, Los Angeles, California.

Received 14 September 2007 ,Revised 21 December 2007 ,Accepted 21 December 2007.

References 

  1. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes (A report of the American College of Cardiology Task Force on clinical data standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001;38:2114–2130
  2. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22
  3. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance and persistence. Am Heart J. 2003;145:438–444
  4. DeWilde S, Carey IM, Bremmer SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994–2001: a case of ageism but not sexism?. Heart. 2003;89:417–421
  5. Walley T, Folino-Gallo P, Stephens P, Van Ganese E. Trends in prescribing and utilizations of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol. 2005;60:543–551
  6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid-lowering statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  7. Eagle KA, Montoye CK, Riba AL, DeFranco AC, Parrish R, Skorcz S. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction. J Am Coll Cardiol. 2005;46:1242–1248
  8. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure (Results of the Optimized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart failure (OPTIMIZE-HF)). Arch Intern Med. 2007;167:1493–1502
  9. Austin PC, Mamdani MM, Juurlink DN, Alter DA, Tu JV. Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality. Am Heart J. 2006;151:969–975
  10. Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005;149:444–450
  11. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials. Heart. 2007;93:914–921
  12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  13. Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, et al. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006;27:2310–2316
  14. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al PROspective Study of Pravastatin in the Elderly at Risk (Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial). Lancet. 2002;360:1623–1630

 This study was supported by the American Heart Association and an unrestricted educational grant from Merck-Schering Plough Partnership.

PII: S0002-9149(08)00044-1

doi: 10.1016/j.amjcard.2007.12.020

American Journal of Cardiology
Volume 101, Issue 9 , Pages 1242-1246 , 1 May 2008

Article Tools

* Image Usage & Resolution